ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer(1,2). The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression(3), which makes ARID1A a poor therapeutic target. Therefore, it is of clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nat Med
Hauptverfasser: Shen, Jianfeng, Ju, Zhenlin, Zhao, Wei, Wang, Lulu, Peng, Yang, Ge, Zhongqi, Nagel, Zachary D., Zou, Jun, Wang, Chen, Kapoor, Prabodh, Ma, Xiangyi, Ma, Ding, Liang, Jiyong, Song, Shumei, Liu, Jinsong, Samson, Leona D., Ajani, Jaffer A., Li, Guo-Min, Liang, Han, Shen, Xuetong, Mills, Gordon B., Peng, Guang
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076433/
https://ncbi.nlm.nih.gov/pubmed/29736026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0012-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge